Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study: Results from the 6-month continuation phase Full Text
Diabetes Care, 09/28/2011
Bergenstal RM et al. – Switching from optimized multiple daily injection (MDI) to sensor–augmented pump (SAP) therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.Methods
- The 6–month, single–crossover continuation phase of Sensor–Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1–year randomized study.
- The primary outcome was change in A1C in the crossover group.
- A1C values were initially lower in the continuing–SAP group than in the crossover group (7.4 vs. 8.0%, P < 0.001).
- A1C values remained reduced in the SAP group. After 3 months on the SAP system, A1C decreased to 7.6% in the crossover group (P < 0.001); this was a significant and sustained decrease among both adults and children (P < 0.05).